menu
    • menu
    [{"orgOrder":0,"company":"Piramal Critical Care","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Piramal Critical Care","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Piramal Critical Care \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Piramal Critical Care \/ Not Applicable"},{"orgOrder":0,"company":"Piramal Critical Care","sponsor":"Brepco Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dopamine","moa":"Adrenergic receptor-beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Piramal Critical Care","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Piramal Critical Care \/ Piramal Critical Care","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Critical Care \/ Piramal Critical Care"}]

    Find Clinical Drug Pipeline Developments & Deals by Piramal Critical Care

    Menu

    Piramal Critical Care

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Piramal Critical Care

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Piramal Critical Care

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dopamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Brepco Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BrePco Biopharma and Piramal Critical Care Announce MHRA Approval for Neoatricon in UK

                            Details : Neoatricon (dopamine hydrochloride) is a Beta-1 adrenergic receptor stimulator, small molecule drug candidate, which is indicated for the treatment of hypotension.

                            Product Name : Neoatricon

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 21, 2025

                            Lead Product(s) : Dopamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Brepco Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Piramal Critical Care

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Piramal Critical Care

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Piramal Critical Care Announces the U.S. Launch of Doxycycline for Injection, USP

                            Details : Doxycycline for Injection, USP is a Protein 30S ribosomal subunit inhibitor, which is used for prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

                            Product Name : Doxycycline-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 16, 2023

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth